# Buprenorphine-Naloxone

## Suboxone 8/2mg

| 藥物代碼 | OSUB |
| :--- | :--- |
| 適應症 | Treatment of opioid dependence. |
| 副作用 | Central nervous system: Headache \(36%\), withdrawal syndrome \(25%; placebo 37%\), pain \(22%\)Dermatologic: Diaphoresis \(14%\)Gastrointestinal: Glossodynia \(film\), oral hypoesthesia \(film\), oral mucosa erythema \(film\) |
| 禁忌 | Hypersensitivity to buprenorphine, naloxone, or any component of the formulation |
| 藥物保存方式 | 室溫 |
| 用法用量 | Sublingual film: Heroin or short-acting opioid dependency: Day 1 induction dose: Initial: Buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg; may titrate dose, based on control of acute withdrawal symptoms, in buprenorphine 2 to 4 mg/naloxone 0.5 to 1 mg increments approximately every 2 hours up to a total dose of buprenorphine 8 mg/naloxone 2 mg. Day 2 induction dose: Up to buprenorphine 16 mg/naloxone 4 mg once daily |
| 肝功能異常 | 無需調整劑量  肝功能損傷的病患的劑量應調整,且應觀察病患是否有突發的鴉片類戒斷的症狀 Moderate impairment: Use with caution during maintenance treatment \(due to reduced clearance of naloxone and potential for reduced buprenorphine efficacy, use may not be appropriate\). Suboxone use is not recommended during induction therapy. Severe impairment: Use is not recommended |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - Probably Compatible |
| 附帶說明 | Buprenorphine PREGNANCY RECOMMENDATION: Limited Human Data—Probably Compatible Naloxone PREGNANCY RECOMMENDATION: Compatible |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | Buprenorphine BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible Naloxone BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible |
| 注射劑給藥建議途徑 | SL |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

